tykerb lapatinib 250 mg

1 INDICATIONS AND USAGE TYKERB ® is indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. TYKERB is a kinase inhibitor indicated in combination with: ( 1 ) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

novartis pharmaceuticals corporation

FDA Reported Adverse Reactions
`[1] diarrhoea` `[2] toxicity to various agents` `[3] completed suicide` `[4] nausea` `[5] drug abuse` `[6] drug ineffective` `[7] death` `[8] fatigue` `[9] vomiting` `[10] off label use`

7 months ago

OVAL ORANGE GS XJG

16 HOW SUPPLIED/STORAGE AND HANDLING The 250 mg tablets of TYKERB are oval, biconvex, orange, and film-coated with ‘GS XJG’ debossed on one side and are available in: Bottles of 150 tablets: NDC 0078-0671-19 Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

More pills like OVAL GS XJG

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

tykerb lapatinib 250 mg

FDA Reported Adverse Reactions [1] diarrhoea [2] toxicity to various agents [3] completed suicide [4] nausea [5] drug abuse [6] drug ineffective [7] death [8] fatigue [9] vomiting [10] off label use

OVAL ORANGE GS XJG

More pills like OVAL GS XJG

FDA Reported Adverse Reactions
`[1] diarrhoea` `[2] toxicity to various agents` `[3] completed suicide` `[4] nausea` `[5] drug abuse` `[6] drug ineffective` `[7] death` `[8] fatigue` `[9] vomiting` `[10] off label use`